Compare Hormel Foods Corp (HRL) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Eli Lilly And Co — how do they compare? Hormel Foods Corp trades at $25.26 (market cap $13.91B), while Eli Lilly And Co trades at $1,140.2 (market cap $1.02T). The key difference: Eli Lilly And Co is far larger — about 73.3× Hormel Foods Corp's market cap, and Hormel Foods Corp pays the higher dividend (4.63%). Which is the better fit depends on your goals.
| HRL | LLY | |
|---|---|---|
Market Cap | $13.91B | $1.02T |
Sector | Consumer Staples | Health |
52-Week High | $29.52 | $1.24K |
52-Week Low | $19.74 | $625.65 |
Enterprise Value | $15.91B | $1.06T |
Dividend Yield | 4.63% | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $25.31, down 0.33% on the day, with a bullish technical outlook and consistent earnings beats. The stock shows a P/E of 29.87 and net income margin of 3.82%, supported by a recent dividend of $0.29. Revenue for 2025 was $12.11B, though net income declined to $478.20M. Analysts maintain a mixed consensus with a $26.33 price target, while the company focuses on portfolio streamlining, such as the sale of its Ceratti business in Brazil (PRNewsWire, 2026-06-29).
HRL offers a stable dividend yield and is near multi-year lows, presenting a value opportunity amid sector weakness. Risks include margin pressure from input costs and competitive threats in the consumer staples space. Institutional sentiment is cautious with 57% hold ratings, but technical indicators suggest potential upside if earnings momentum continues.
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
